Richard Lynn Ingram

US Patent:

7138264, Nov 21, 2006

Filed:

May 21, 2003

Appl. No.:

10/444257

Inventors:

Brian M. Beyer - Lincroft NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York City NY, US
Corey Strickland - Martinsville NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12N 9/64
C12N 5/10
C12Q 1/37
A01N 37/18
A61K 38/00

US Classification:

435226, 435219, 435 23, 435325, 4352523, 514 2, 530300

Abstract:

The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

US Patent:

7529628, May 5, 2009

Filed:

Oct 18, 2006

Appl. No.:

11/582710

Inventors:

Brian M. Beyer - Lincroft NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York NY, US
Corey O. Strickland - Martinsville NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

G01N 33/48
G06G 7/58

US Classification:

702 19, 703 11

Abstract:

The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

US Patent:

7700753, Apr 20, 2010

Filed:

Apr 8, 2009

Appl. No.:

12/420323

Inventors:

Brian M. Beyer - Aberdeen NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York NY, US
Corey O. Strickland - Martinsville NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07H 21/04

US Classification:

536 232, 536 231

Abstract:

The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

US Patent:

7807160, Oct 5, 2010

Filed:

Aug 29, 2006

Appl. No.:

11/511635

Inventors:

Leonard G. Presta - San Francisco CA, US
Brian M. Beyer - Matawan NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York NY, US
Yan-Hui Liu - Murray Hill NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241331, 53038823

Abstract:

Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e. g. in treatment of inflammatory, autoimmune, and proliferative disorders.

US Patent:

7824897, Nov 2, 2010

Filed:

Feb 9, 2010

Appl. No.:

12/702760

Inventors:

Brian M. Beyer - Lincroft NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York NY, US
Corey O. Strickland - Martinsville NJ, US

Assignee:

Schering Corp. - Kenilworth NJ

International Classification:

C12N 9/64
C12N 5/10
C12Q 1/37
G01N 31/00

US Classification:

435226, 435219, 435 23, 435325, 4352523, 436 4

Abstract:

The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

US Patent:

7968683, Jun 28, 2011

Filed:

May 7, 2009

Appl. No.:

12/437116

Inventors:

Brian M. Beyer - Lincroft NJ, US
Alan W. Hruza - Hackettstown NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Vincent S. Madison - Ukiah CA, US
Andrew J. Prongay - Billerica MA, US
Paul Reichert - Montville NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 35/14
A61K 38/48
C07K 1/00
C07K 14/00
C07K 17/00
G01N 31/00

US Classification:

530384, 436 4

Abstract:

The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

US Patent:

8513389, Aug 20, 2013

Filed:

Jun 22, 2012

Appl. No.:

13/530854

Inventors:

Leonard G. Presta - San Francisco CA, US
Brian M. Beyer - Matawan NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Peter Orth - New York NY, US
Yan-Hui Liu - Murray Hill NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 16/24

US Classification:

5303871, 5303881, 53038823

Abstract:

Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e. g. in treatment of inflammatory, autoimmune, and proliferative disorders.

US Patent:

8206943, Jun 26, 2012

Filed:

Jun 29, 2009

Appl. No.:

12/493752

Inventors:

Brian M. Beyer - Matawan NJ, US
Thomas Hesson - Burlington MA, US
Hung V. Le - Rockaway NJ, US
Andrew J. Prongay - Billerica MA, US
Krishna Kalghatgi - Westborough MA, US
Jennifer Joanne Gesell - Allentown NJ, US
Richard N. Ingram - Scotch Plains NJ, US
Michael R. Ziebell - Arlington MA, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C12Q 1/37

US Classification:

435 23

Abstract:

The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.